← All Cg Oncology, INC filings

Cg Oncology, INC S-1 registration statements

Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.

NASDAQ
CGON
Cg Oncology, INC
S-1/A: CG Oncology Files Amendment to S-1 Registration for Public Offering
CG Oncology has filed an amendment to its S-1 registration statement, primarily to include exhibits related to the underwriting agreement and legal opinion, as it prepares for its public offering.
NASDAQ
CGON
Cg Oncology, INC
S-1: CG Oncology Files for Secondary Offering to Fund Bladder Cancer Drug Development
CG Oncology is seeking to raise capital through a secondary stock offering to advance its bladder cancer treatment, cretostimogene, through clinical trials and towards potential commercialization.
NASDAQ
CGON
Cg Oncology, INC
S-1MEF: CG Oncology Files to Increase IPO Share Offering by 3.45 Million Shares
CG Oncology seeks to increase its IPO share offering by 3.45 million shares, including an underwriter option, representing no more than 20% of the initial offering price.
NASDAQ
CGON
Cg Oncology, INC
S-1/A: CG Oncology Eyes Nasdaq Debut with $289 Million IPO to Advance Bladder Cancer Therapy
CG Oncology is seeking to raise $289 million through an initial public offering to fund the development and commercialization of its bladder cancer therapeutic, cretostimogene.
NASDAQ
CGON
Cg Oncology, INC
S-1/A: CG Oncology Eyes Nasdaq Debut with $16-$18 IPO, Advancing Bladder Cancer Therapy
CG Oncology, a late-stage biopharmaceutical company, is set to launch its IPO on the Nasdaq, aiming to raise capital for its bladder cancer therapeutic, cretostimogene.